It took some time but Johnson & Johnson’s Spravato (esketamine), a nasal spray approved for treatment-resistant depression in 2019, is poised to become a blockbuster seller this year. J&J reported second quarter financial results on 17 July, with Spravato being one of 10 drugs in the innovative medicines portfolio that turned in double-digit growth.
Key Takeaways
- Spravato faced several commercial hurdles when it launched for treatment-resistant depression in in 2019, but Q2 revenues have it on track to become a blockbuster.
- Spravato is one of 10 drugs in J&J's innovative medicines portfolio that turned in double-digit growth in the second quarter
Of those newer high-growth products, Spravato was the fastest growing, with revenues up 60.2% to $271m, putting it on a blockbuster trajectory
